Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.
Small cell lung cancer (SCLC) is an aggressive disease, difficult to treat. There have been no significant therapeutic advances over platinum and etoposide chemotherapy in the last 20 years until the introduction of immunotherapy. In 2020 atezolizumab, an immune checkpoint inhibitor against PD-L1 was approved in Italy in combination with carboplatin and etoposide for the first-line treatment of patients with extensive stage disease (ES-SCLC), becoming the new standard treatment. On May 20, 2021, a virtual meeting, directed by profs. Federico Cappuzzo and Emilio Bria, was held in which 14 clinicians from different oncology centers in Lazio, Umbria and Sardinia discussed the issues of ES-SCLC patients treatment, after the advent of immunotherapy. The aim of the meeting was to share their clinical experience and to provide a series of practical indications that can support clinicians in the management of ES-SCLC patients in first-line with chemo-immunotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
Recenti progressi in medicina - 112(2021), 10 vom: 24. Okt., Seite 639-646 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Gestione del paziente con microcitoma nelle regioni Lazio, Umbria e Sardegna |
|---|
| Beteiligte Personen: |
Minuti, Gabriele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6PLQ3CP4P3 |
|---|
| Anmerkungen: |
Date Completed 19.04.2022 Date Revised 19.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1701/3679.36653 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331882760 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331882760 | ||
| 003 | DE-627 | ||
| 005 | 20231225214442.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1701/3679.36653 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM331882760 | ||
| 035 | |a (NLM)34647533 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Minuti, Gabriele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia. |
| 246 | 3 | 3 | |a Gestione del paziente con microcitoma nelle regioni Lazio, Umbria e Sardegna |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2022 | ||
| 500 | |a Date Revised 19.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Small cell lung cancer (SCLC) is an aggressive disease, difficult to treat. There have been no significant therapeutic advances over platinum and etoposide chemotherapy in the last 20 years until the introduction of immunotherapy. In 2020 atezolizumab, an immune checkpoint inhibitor against PD-L1 was approved in Italy in combination with carboplatin and etoposide for the first-line treatment of patients with extensive stage disease (ES-SCLC), becoming the new standard treatment. On May 20, 2021, a virtual meeting, directed by profs. Federico Cappuzzo and Emilio Bria, was held in which 14 clinicians from different oncology centers in Lazio, Umbria and Sardinia discussed the issues of ES-SCLC patients treatment, after the advent of immunotherapy. The aim of the meeting was to share their clinical experience and to provide a series of practical indications that can support clinicians in the management of ES-SCLC patients in first-line with chemo-immunotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Etoposide |2 NLM | |
| 650 | 7 | |a 6PLQ3CP4P3 |2 NLM | |
| 650 | 7 | |a Carboplatin |2 NLM | |
| 650 | 7 | |a BG3F62OND5 |2 NLM | |
| 700 | 1 | |a Stefani, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Carpano, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a D'Argento, Ettore |e verfasserin |4 aut | |
| 700 | 1 | |a Giusti, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Martelli, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Metro, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Gelibter, Alain J |e verfasserin |4 aut | |
| 700 | 1 | |a Antonini Cappellini, Gian Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Carta, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Fadda, Giovanni Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Nelli, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Ricciardi, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Russano, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Bria, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Cappuzzo, Federico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Recenti progressi in medicina |d 1948 |g 112(2021), 10 vom: 24. Okt., Seite 639-646 |w (DE-627)NLM000023124 |x 2038-1840 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2021 |g number:10 |g day:24 |g month:10 |g pages:639-646 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1701/3679.36653 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2021 |e 10 |b 24 |c 10 |h 639-646 | ||